SEC 13F Intelligence

Managers / Q3 2021 · view latest →

Birchview Capital, LP

CIK 0001618205 · 688 PINE STREET, SUITE D, C/O BIRCHVIEW CAPITAL, BURLINGTON, VT, 05401 · 802-923-3826

Reported Value
$147M
Q3 2021
Positions
64
Filings on Record
39
2019–present window
Filed
Nov 12, 2021
original filing

Summary

Birchview Capital, LP reported $147M in U.S.-listed holdings across 64 positions for Q3 2021.

The portfolio is heavily concentrated: BMY alone accounts for 32.1% of reported value.

Compared with Q2 2021, the fund opened 5 new positions and exited 3.

Portfolio Metrics

Turnover
+4.9%
vs prior filed quarter
Top-10 Concentration
+70.4%
share of reported value
Largest Position
+32.1%
Bristol Myers Squibb
New / Exited
5 / 3
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’18: $106MQ4 ’18Q1 ’19: $160MQ2 ’19: $164MQ3 ’19: $150MQ4 ’19: $138MQ4 ’19Q1 ’20: $113MQ2 ’20: $165MQ3 ’20: $150MQ4 ’20: $174MQ4 ’20Q1 ’21: $168MQ2 ’21: $167MQ3 ’21: $147MQ4 ’21: $155MQ4 ’21Q1 ’22: $139MQ2 ’22: $137MQ3 ’22: $142MQ1 ’23: $127,725Q1 ’23Q3 ’23: $117MQ4 ’23: $128MQ1 ’24: $122MQ2 ’24: $108MQ2 ’24Q3 ’24: $115MQ4 ’24: $123MQ1 ’25: $115MQ2 ’25: $101MQ2 ’25Q3 ’25: $132MQ4 ’25: $171MQ1 ’26: $176Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 76.6%Other: 23.4%
  • Common Stock · 76.6% · $113M
  • Other · 23.4% · $34M

Quarter-over-Quarter Changes full breakdown →

vs Q2 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
GOSSGOSSAMER BIO INCNEW+40.0K40.0K+$503,000$503,000
AVEO PHARMACEUTICALS INCNEW+40.0K40.0K+$247,000$247,000
OPHTEURIVERIC BIO INCNEW+15.0K15.0K+$244,000$244,000
IRTCIRHYTHM TECHNOLOGIES INCNEW+4.0K4.0K+$234,000$234,000
YIELD10 BIOSCIENCE INCNEW+18.8K18.8K+$113,000$113,000
PTGXPROTAGONIST THERAPEUTICS INCADDED+28.0K38.0K+$224,000$673,000
CYTKCYTOKINETICS INCADDED+15.0K25.0K+$696,000$894,000
TRANSLATE BIO INCSOLD OUT−30.0K0−$826,000$0

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q3 2021

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1BMYBRISTOL-MYERS SQUIBB COhistory →COM32.05%$47M796.1K
2ACCELERATE DIAGNOSTICS INCCOM8.91%$13M2.25M
3BIODESIX INCCOM6.18%$9M1.10M
4QDEL*QUIDEL CORPhistory →COM5.73%$8M59.7K
5NBIXNEUROCRINE BIOSCIENCES INChistory →COM5.23%$8M80.2K
6FHTXFOGHORN THERAPEUTICS INChistory →COM2.98%$4M314.1K
7BIIBBIOGEN INChistory →COM2.43%$4M12.6K
8BDQMALBIREO PHARMA INChistory →COM2.40%$4M113.0K
9UTHUNITED THERAPEUTICS CORPhistory →COM2.26%$3M18.0K
10ACADACADIA PHARMACEUTICALS INChistory →COM2.25%$3M199.4K
11PROTHENA CORP PLCSHS1.95%$3M40.2K
12MASI*MASIMO CORPhistory →COM1.47%$2M8.0K
13XLRNACCELERON PHARMA INChistory →COM1.25%$2M10.7K
14CLRUSDCONTINENTAL RESOURCES INChistory →COM1.21%$2M38.6K
15HROWHARROW HEALTH INChistory →COM1.11%$2M180.0K
16BLUEBIRD BIO INCCOM1.09%$2M84.0K
17ALKERMES PLCSHS1.05%$2M50.0K
18AMARIN CORP PLCSPONS ADR NEW1.04%$2M300.0K
19KPTIEURKARYOPHARM THERAPEUTICS INCCOM0.97%$1M246.0K
20BIOHAVEN PHARMACEUTICAL HOLDING CO LTDCOM0.95%$1M10.0K
21VNDAVANDA PHARMACEUTICALS INCCOM0.93%$1M80.0K
22ETRNUSDEQUITRANS MIDSTREAM CORPORATIOCOM0.92%$1M133.1K
23ARNAEURARENA PHARMACEUTICALS INCCOM0.89%$1M22.0K
24NKTREURNEKTAR THERAPEUTICSCOM0.88%$1M72.0K
25ARVNARVINAS INCCOM0.84%$1M15.0K
26OVVOVINTIV INCCOM0.76%$1M34.2K
27IMGNEURIMMUNOGEN INCCOM0.73%$1M190.0K
28CGEMCULLINAN ONCOLOGY INCCOM0.69%$1M45.1K
29HTDCORCEPT THERAPEUTICS INCCOM0.67%$984,00050.0K
30CYTKCYTOKINETICS INCCOM0.61%$894,00025.0K
31PGNYPROGYNY INCCOM0.57%$840,00015.0K
32SOLENO THERAPEUTICS INCCOM0.55%$811,000876.9K
33CFRXEURCONTRAFECT CORPCOM0.55%$810,000200.0K
344XC1KALVISTA PHARMACEUTICALS INCCOM0.47%$698,00040.0K
35PTGXPROTAGONIST THERAPEUTICS INCCOM0.46%$673,00038.0K
36PXDEURPIONEER NATURAL RESOURCES COCOM0.43%$633,0003.8K
37INARI MEDICAL INCCOM0.39%$568,0007.0K
38GTHXEURG1 THERAPEUTICS INCCOM0.37%$537,00040.0K
39ZNTLZENTALIS PHARMACEUTICALS INCCOM0.36%$533,0008.0K
40ANGION BIOMEDICA CORPCOM0.36%$531,00054.4K
41TURNING POINT THERAPEUTICS INCCOM0.36%$531,0008.0K
42GOSSGOSSAMER BIO INCCOM0.34%$503,00040.0K
43TGTXTG THERAPEUTICS INCCOM0.34%$499,00015.0K
44CCXIEURCHEMOCENTRYX INCCOM0.29%$428,00025.0K
45PROGENITY INCCOM0.28%$410,000270.0K
46XNCRXENCOR INCCOM0.27%$402,00012.3K
47APLSUSDAPELLIS PHARMACEUTICALS INCCOM0.27%$396,00012.0K
48STOKSTOKE THERAPEUTICS INCCOM0.26%$382,00015.0K
49AM6AMICUS THERAPEUTICS INCCOM0.25%$363,00038.0K
50ELUTAZIYO BIOLOGICS INCCOM0.24%$348,00050.0K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$176M73May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$171M68Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$132M69Nov 13, 202513F-HRchanges · EDGAR ↗
Q2 2025$101M71Aug 14, 202513F-HRchanges · EDGAR ↗
Q1 2025$115M68May 15, 202513F-HRchanges · EDGAR ↗
Q4 2024$123M68Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$115M62Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$108M61Aug 13, 202413F-HRchanges · EDGAR ↗
Q1 2024$122M60May 14, 202413F-HRchanges · EDGAR ↗
Q4 2023$128M59Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$117M52Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023Under review54Aug 8, 202313F-HRchanges · EDGAR ↗
Q1 2023$127,72555May 12, 202313F-HRchanges · EDGAR ↗
Q4 2022Under review57Feb 3, 202313F-HRchanges · EDGAR ↗
Q3 2022$142M60Nov 28, 2022RESTATEMENTchanges · EDGAR ↗
Q2 2022$137M64Aug 12, 202213F-HRchanges · EDGAR ↗
Q1 2022$139M63May 13, 202213F-HRchanges · EDGAR ↗
Q4 2021$155M67Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$147M64Nov 12, 202113F-HRchanges · EDGAR ↗
Q2 2021$167M62Aug 10, 202113F-HRchanges · EDGAR ↗
Q1 2021$168M54May 14, 202113F-HRchanges · EDGAR ↗
Q4 2020$174M48Feb 9, 202113F-HRchanges · EDGAR ↗
Q3 2020$150M50Nov 12, 2020RESTATEMENTchanges · EDGAR ↗
Q2 2020$165M51Aug 10, 202013F-HRchanges · EDGAR ↗
Q1 2020$113M46May 12, 202013F-HRchanges · EDGAR ↗
Q4 2019$138M52Feb 12, 202013F-HRchanges · EDGAR ↗
Q3 2019$150M50Nov 12, 201913F-HRchanges · EDGAR ↗
Q2 2019$164M54Aug 6, 201913F-HRchanges · EDGAR ↗
Q1 2019$160M54May 3, 201913F-HRchanges · EDGAR ↗
Q4 2018$106M52Feb 6, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.